Global Calcineurin Inhibitors Market – Industry Trends and Forecast to 2030

Calcineurin Inhibitors Market Analysis and Size

Autoimmune illnesses are among the most common diseases in the United States, affecting more than 23.5 million people, according to the National Institute of Environmental Health Sciences (NIH). Calcineurin inhibitors are a class of medications used to treat allograft recipients with inflammatory diseases including atopic dermatitis, rheumatoid arthritis, and postoperative immunosuppression. Calcineurin inhibitors are "immunosuppressants" because they inhibit calcineurin, an enzyme that stimulates immunological T-cells. T lymphocytes are a type of leukocyte (white blood cell) that is required for cell-mediated immunity.                         

Data Bridge Market Research analyzes that the calcineurin inhibitors market which was USD 9.08 billion in 2022, would rocket up to USD 20.47 billion by 2030, and is expected to undergo a CAGR of 10.7% during the forecast period. “Psoriasis” dominates the diseases segment of the calcineurin inhibitors market due to rise in the prevalence of psoriasis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Calcineurin inhibitors are drugs that stop calcineurin from working. Calcineurin is an enzyme that activates immune system T-cells. T-cells (also known as T-lymphocytes) are white blood cells that play an important part in cell-mediated immunity. Calcineurin inhibitors are classified as immunosuppressants because they suppress the immune system. When previous therapies have failed, topical calcineurin inhibitors (pimecrolimus, tacrolimus) can be used to treat inflammatory skin diseases including atopic dermatitis. Calcineurin inhibitors (cyclosporine, tacrolimus) are used to induce and maintain postoperative immunosuppression.

Calcineurin Inhibitors Market Dynamics

Drivers

• Increasing prevalence of autoimmune disorders

Calcineurin inhibitors are vital in the management of autoimmune diseases like rheumatoid arthritis and psoriasis. As the incidence of autoimmune disorders rises, the demand for these inhibitors increases.

• Growing organ transplantations

Calcineurin inhibitors play a crucial role in post-transplant immunosuppression, preventing organ rejection. With a rising number of organ transplant procedures globally, the demand for these drugs is on the upswing.

• Advancements in drug delivery

Innovations in drug delivery methods, such as sustained-release formulations and topical preparations, enhance patient compliance. These advancements are driving the market growth by making the medications more accessible and easier to use.

Opportunities

• Biological Calcineurin Inhibitors:

Research into biological calcineurin inhibitors, such as monoclonal antibodies targeting specific pathways, offers promising opportunities. These biologics may provide more targeted therapies with potentially reduced side effects.

• Increasing awareness

Educational initiatives and awareness campaigns about autoimmune disorders and the availability of effective treatments can expand the market. Better-informed patients are more likely to seek appropriate treatments, boosting market growth

• Market expansion in developing regions

Penetration into untapped markets in developing regions, where the prevalence of autoimmune disorders is rising, presents significant growth opportunities. Accessible and affordable calcineurin inhibitors can cater to a larger patient base.

Restraints/Challenges

• Adverse effects

Calcineurin inhibitors are associated with adverse effects like nephrotoxicity, hypertension, and increased susceptibility to infections. Concerns about these side effects limit their long-term use, impacting market growth.

• Patent expiry and generic competition

The expiration of patents for established calcineurin inhibitors leads to the entry of generic versions into the market. While this promotes affordability, it also intensifies competition among manufacturers, affecting profit margins.

This calcineurin inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the calcineurin inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2022, Sun Pharma had announced the launch of dry eye treatment product named Cequa (cyclosporine ophthalmic solution 0.09 per cent w/v). It is a calcineurin inhibitor immunomodulator. The medication is the first dry eye treatment in Canada to utilize nanomicellar (NCELL) technology, that enhances cyclosporine bioavailability and physicochemical stability to promote ocular tissue penetration

Global Calcineurin Inhibitors Market Scope

The calcineurin inhibitors market is segmented on the basis of diseases, drug, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases

• Atopic Dermatitis
• Postoperative Immunosuppression
• Ulcerative Colitis
• Psoriasis
• Keratoconjunctivitis
• Others

Drug

• Cyclosporine
• Tacrolimus
• Pimecrolimus
• Others

Route of Administration

• Oral
• Topical
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Calcineurin Inhibitors Market Regional Analysis/Insights

The calcineurin inhibitors market is analyzed and market size insights and trends are provided by country, diseases, drug, route of administration, end-users and distribution channel as referenced above.

The countries covered in the calcineurin inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America is expected to dominate the calcineurin inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of atopic dermatitis and rising healthcare expenditure will further propel the market’s growth rate in this region. In addition, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.

Asia-Pacific is expected to be the fastest growing region during the forecast period of 2023-2030 due to high presence of generic manufacturer in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

Calcineurin inhibitors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for calcineurin inhibitors market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the calcineurin inhibitors market. The data is available for historic period 2010-2020.

Competitive Landscape and Calcineurin Inhibitors Market Share Analysis

The calcineurin inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to calcineurin inhibitors market.

Some of the major players operating in the calcineurin inhibitors market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson (U.S.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• LEO Pharma A/S (Denmark)
• Aurobindo Pharma (India)
• Lupin (India)
• Eli Lilly and Company (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Bausch Health Companies Inc. (Canada)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc. (U.S.)
• Allergan (Ireland)

SKU-53275